Cue Biopharma Past Earnings Performance
Past criteria checks 0/6
Cue Biopharma's earnings have been declining at an average annual rate of -6.1%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 15.3% per year.
Key information
-6.1%
Earnings growth rate
10.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 15.3% |
Return on equity | -136.8% |
Net Margin | -924.1% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money
Apr 16Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?
Dec 30Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?
Aug 11Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug
Oct 04Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt
Sep 23News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat
Aug 26Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates
Aug 10Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%
May 18Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 12Cue Biopharma: A First Assessment
May 11Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Mar 19Cue Biopharma: Too Long To Arrive At Topline Trial Data
Feb 23We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth
Nov 04Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer
Jun 10Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth
Jun 07Cue Biopharma's CUE-101 shows encouraging action in HPV+ head and neck cancer patients
May 10How Many Cue Biopharma, Inc. (NASDAQ:CUE) Shares Did Insiders Buy, In The Last Year?
Mar 21We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Feb 22Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders?
Jan 27Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022
Jan 07Reflecting on Cue Biopharma's (NASDAQ:CUE) Share Price Returns Over The Last Year
Dec 25Independent Director Aaron Fletcher Just Bought 3.9% More Shares In Cue Biopharma, Inc. (NASDAQ:CUE)
Nov 29We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Nov 24Cue Biopharma (CUE) Investor Presentation - Slideshow
Nov 20Cue Biopharma EPS beats by $0.12, misses on revenue
Nov 17Revenue & Expenses BreakdownBeta
How Cue Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 5 | -51 | 19 | 0 |
30 Sep 23 | 4 | -52 | 16 | 0 |
30 Jun 23 | 2 | -52 | 16 | 0 |
31 Mar 23 | 0 | -52 | 15 | 0 |
31 Dec 22 | 1 | -53 | 19 | 0 |
30 Sep 22 | 9 | -47 | 17 | 0 |
30 Jun 22 | 12 | -49 | 18 | 0 |
31 Mar 22 | 14 | -46 | 18 | 0 |
31 Dec 21 | 15 | -44 | 17 | 0 |
30 Sep 21 | 7 | -47 | 16 | -5 |
30 Jun 21 | 5 | -44 | 15 | 0 |
31 Mar 21 | 4 | -44 | 15 | 0 |
31 Dec 20 | 3 | -45 | 15 | 0 |
30 Sep 20 | 4 | -43 | 14 | 5 |
30 Jun 20 | 4 | -40 | 14 | 0 |
31 Mar 20 | 4 | -38 | 13 | 0 |
31 Dec 19 | 3 | -37 | 13 | 0 |
30 Sep 19 | 3 | -39 | 14 | 0 |
30 Jun 19 | 2 | -45 | 14 | 0 |
31 Mar 19 | 2 | -43 | 13 | 0 |
31 Dec 18 | 1 | -39 | 11 | 0 |
30 Sep 18 | 1 | -38 | 8 | 0 |
30 Jun 18 | 0 | -30 | 6 | 0 |
31 Mar 18 | 0 | -27 | 5 | -2 |
31 Dec 17 | 0 | -23 | 4 | 0 |
30 Sep 17 | 0 | -16 | 4 | 2 |
30 Jun 17 | 0 | -13 | 4 | 3 |
31 Mar 17 | 0 | -10 | 4 | 6 |
31 Dec 16 | 0 | -8 | 3 | 5 |
Quality Earnings: CUE is currently unprofitable.
Growing Profit Margin: CUE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CUE is unprofitable, and losses have increased over the past 5 years at a rate of 6.1% per year.
Accelerating Growth: Unable to compare CUE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CUE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: CUE has a negative Return on Equity (-136.8%), as it is currently unprofitable.